Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACST Acasti Pharma

Trading 07-02 11:35:14 EDT

2.95

+0.06

+2.08%

High3.05	Low2.95	Vol1.02K
Open3.05	D1 Closing2.89	Amplitude3.46%
Mkt Cap27.73M	Tradable Cap17.32M	Total Shares9.40M
T/O3.00K	T/O Rate0.02%	Tradable Shares5.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ACST","market":"US","secType":"STK","nameCN":"Acasti Pharma","latestPrice":2.95,"timestamp":1719934358622,"preClose":2.89,"halted":0,"volume":1024,"delay":0,"floatShares":5870533,"shares":9399404,"eps":-1.348812,"marketStatus":"Trading","change":0.06,"latestTime":"07-02 11:35:14 EDT","open":3.05,"high":3.05,"low":2.95,"amount":3001.7600512,"amplitude":0.034602,"askPrice":2.91,"askSize":10,"bidPrice":2.86,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.348812,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1719950400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1357534800000,"exchange":"NASDAQ","adjPreClose":2.89,"preHourTrading":{"tag":"盘前","latestPrice":3,"preClose":2.89,"latestTime":"09:17 EDT","volume":17,"amount":51,"timestamp":1719926231465},"postHourTrading":{"tag":"盘后","latestPrice":2.92,"preClose":2.92,"latestTime":"17:40 EDT","volume":52,"amount":154.52,"timestamp":1719870046087},"volumeRatio":0.127225},"requestUrl":"/m/hq/s/ACST","defaultTab":"news","newsList":[{"id":"2448773994","title":"Is Acasti Pharma (NASDAQ:ACST) In A Good Position To Invest In Growth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2448773994","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448773994?lang=en_us&edition=fundamental","pubTime":"2024-07-01 20:17","pubTimestamp":1719836279,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.So, the natural question for Acasti Pharma  shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.When Might Acasti Pharma Run Out Of Money?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acasti-pharma-nasdaq-acst-good-121759581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","QLD","LU2210149790.SGD","QID","NDAQ","TQQQ","SQQQ",".IXIC","ACST","BK4007","BK4588","BK4112","BK4585","MNQmain","PSQ","LU2210150020.SGD","QQQ","NQmain"],"gpt_icon":0},{"id":"2448310960","title":"Strong Buy: Acasti Pharma’s GTX-104 Poised for Standard of Care in aSAH with Promising Market Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2448310960","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2448310960?lang=en_us&edition=fundamental","pubTime":"2024-07-01 18:15","pubTimestamp":1719828953,"startTime":"0","endTime":"0","summary":"Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Acasti Pharma (ACST – Research Report). The associated price target is $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-buy-acasti-pharmas-gtx-104-poised-for-standard-of-care-in-asah-with-promising-market-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-buy-acasti-pharmas-gtx-104-poised-for-standard-of-care-in-asah-with-promising-market-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZL793.SGD","IE00B19Z4B17.USD","ACST","BK4007","SMP","IE00B66KJ199.SGD","IE0031619046.USD","BK4124","GTX"],"gpt_icon":0},{"id":"2446459833","title":"BRIEF-Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2446459833","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446459833?lang=en_us&edition=fundamental","pubTime":"2024-06-28 04:31","pubTimestamp":1719520315,"startTime":"0","endTime":"0","summary":"Acasti Pharma Inc   :   * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL PHASE 3 STRIVE-ON SAFETY TRIAL   * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS IN LATE 2024 TO EARLY 2025   * ACASTI PHARMA INC:  ANTICIPATE STAYING ON TRACK FOR A POTENTIAL NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025Source text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","LU2357305700.SGD","ACST","LU1720051108.HKD","LU1854103824.USD","LU1861215975.USD","BK4585","LU1720051017.SGD","LU1861219969.SGD","BK4007","LU1861220033.SGD","LU1854104046.USD","BK4512","LU1861214812.USD","LU1978683503.SGD","LU0348723411.USD","BK4588","LU1548497426.USD","BK4141","LU0124384867.USD"],"gpt_icon":0},{"id":"2446393403","title":"Craig-Hallum Sticks to Their Buy Rating for Acasti Pharma (ACST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2446393403","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446393403?lang=en_us&edition=fundamental","pubTime":"2024-06-26 20:57","pubTimestamp":1719406624,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Acasti Pharma (ACST – Research Report) today and set a price target of $6.00. T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-acasti-pharma-acst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-acasti-pharma-acst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST"],"gpt_icon":0},{"id":"2445764203","title":"Acasti Pharma GAAP EPS of -$1.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2445764203","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445764203?lang=en_us&edition=fundamental","pubTime":"2024-06-21 21:17","pubTimestamp":1718975829,"startTime":"0","endTime":"0","summary":"Acasti Pharma press release  : FY  GAAP EPS of -$1.35.At March 31, 2024, the Company had cash and cash equivalents of $23.0 million, as compared to $27.9 million as of March 31, 2023. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4117917-acasti-pharma-gaap-eps-of-1_35","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ACST"],"gpt_icon":0},{"id":"2439580826","title":"Acasti Pharma to Attend BIO International Convention 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2439580826","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439580826?lang=en_us&edition=fundamental","pubTime":"2024-05-29 04:05","pubTimestamp":1716926700,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., May  28, 2024  (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of n","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/28/2889416/0/en/Acasti-Pharma-to-Attend-BIO-International-Convention-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4121","BK4007","BIO","BK4585","ACST"],"gpt_icon":0},{"id":"2437336410","title":"Insider Stock Buying Reaches US$2.50m On Acasti Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2437336410","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437336410?lang=en_us&edition=fundamental","pubTime":"2024-05-21 20:56","pubTimestamp":1716296165,"startTime":"0","endTime":"0","summary":"In the last year, multiple insiders have substantially increased their holdings of Acasti Pharma Inc.  stock, indicating that insiders' optimism about the company's prospects has increased.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.The Last 12 Months Of Insider Transactions At Acasti Pharma. The Independent Chairman Vimal Kavuru made the biggest insider purchase in the last 12 months. That single transaction was for US$1.3m worth of shares at a price of US$1.85 each. We do like to see buying, but this purchase was made at well below the current price of US$2.71. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open mar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-stock-buying-reaches-us-125605468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2428292586","title":"We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2428292586","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428292586?lang=en_us&edition=fundamental","pubTime":"2024-04-20 20:34","pubTimestamp":1713616467,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acst/acasti-pharma/news/were-keeping-an-eye-on-acasti-pharmas-nasdaqacst-cash-burn-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACST","LU2210150020.SGD","QQQ","PSQ","QID","BK4007","BK4588","NQmain","MNQmain","LU2095319765.USD","LU2210149790.SGD","BK4112","QLD","SQQQ",".IXIC","BK4585","TQQQ","NDAQ"],"gpt_icon":0},{"id":"2422030187","title":"12 Best Biotech Penny Stocks to Invest In","url":"https://stock-news.laohu8.com/highlight/detail?id=2422030187","media":"Insider Monkey","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422030187?lang=en_us&edition=fundamental","pubTime":"2024-03-25 03:54","pubTimestamp":1711310061,"startTime":"0","endTime":"0","summary":"In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In.Investors eager to ride the optimism in the biotech sector this year should carefully look at the growth plans of big biotech companies that are spending billions in research and development to stay ahead of the curve. The comments of Dave Ricks, the CEO of Eli Lilly and Company , can provide some context into this. During the fourth quarter earnings call at the beginning of February, Ricks highlighted the efforts of his company towards increasing the resilience of drug manufacturing and growing top lines through key partnerships.This progress will serve as a foundation to drive top-tier revenue growth and margin expansion over","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_FbrCaz8LS5fa8LCm7g0qw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/36ee815c30e063a02613bdfb330dbfe2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_FbrCaz8LS5fa8LCm7g0qw--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/36ee815c30e063a02613bdfb330dbfe2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/12-best-biotech-penny-stocks-195421471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","IBIO","QID","NQmain","AGRX","LU1718418525.SGD","BK4139","LU0320765059.SGD",".IXIC","LU1496350502.SGD","QLD","BK4588","LU0466842654.USD","ASXC","LU1496350171.SGD","IE00B2B36J28.USD","LFWD","BK4566","LU1244550494.USD","QQQ","LU0640476718.USD","LU0820561818.USD","LU1430594728.SGD","LU1267930490.SGD","IE00BFTCPJ56.SGD","LLY","LU1267930730.SGD","LU1829250122.USD","LU1064131342.USD","LU2602419157.SGD","LU1712237335.SGD","GSK","LU0689472784.USD","LU0198837287.USD","ABBV","ENTX","GSK.UK","LU0097036916.USD","LU1623119135.USD","PSQ","BK4585","LU2265009873.SGD","MNQmain","LU0456855351.SGD","CYCN","LU0170899867.USD","LU0820561909.HKD","ACST","TQQQ","LU1839511570.USD","SQQQ"],"gpt_icon":0},{"id":"2411352814","title":"Acasti Pharma (ACST) Gets a Buy from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2411352814","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2411352814?lang=en_us&edition=fundamental","pubTime":"2024-02-13 21:36","pubTimestamp":1707831363,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Acasti Pharma (ACST – Research Report). The company’s ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acasti-pharma-acst-gets-a-buy-from-craig-hallum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acasti-pharma-acst-gets-a-buy-from-craig-hallum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACST","BK4007"],"gpt_icon":0},{"id":"2411829100","title":"Acasti Pharma GAAP EPS of -$0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2411829100","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2411829100?lang=en_us&edition=fundamental","pubTime":"2024-02-13 00:14","pubTimestamp":1707754447,"startTime":"0","endTime":"0","summary":"Acasti Pharma press release  : Q3  GAAP EPS of -$0.21.The Company’s cash, cash equivalents and short-term investments as of December 31, 2023, were $25.1 million. The Company believes its cash, cash equivalents and short-term investments are sufficient to fund its operations into the second calendar quarter of 2026.More on Acasti Pharma  Seeking Alpha’s Quant Rating on Acasti Pharma Historical earnings data for Acasti Pharma Financial information for Acasti Pharma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4065578-acasti-pharma-gaap-eps-of-0_21","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ACST"],"gpt_icon":0},{"id":"2410158844","title":"Acasti Pharma Q3 EPS $(0.21) Up From $(0.52) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2410158844","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2410158844?lang=en_us&edition=fundamental","pubTime":"2024-02-12 22:12","pubTimestamp":1707747142,"startTime":"0","endTime":"0","summary":"Acasti Pharma (NASDAQ:ACST) reported quarterly losses of $(0.21) per share. This is a 59.62 percent increase over losses of $(0.52) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/02/37066199/acasti-pharma-q3-eps-0-21-up-from-0-52-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACST"],"gpt_icon":0},{"id":"2410844545","title":"BRIEF-Acasti Announces Third Fiscal Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2410844545","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2410844545?lang=en_us&edition=fundamental","pubTime":"2024-02-12 21:10","pubTimestamp":1707743424,"startTime":"0","endTime":"0","summary":"Feb 12 (Reuters) - Acasti Pharma Inc   :   * ACASTI ANNOUNCES THIRD FISCAL QUARTER 2024 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS   * PROJECTED CASH RUNWAY EXTENDS INTO SECOND CALENDAR QUARTER 2026Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACST"],"gpt_icon":0},{"id":"2410684100","title":"Press Release: Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2410684100","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2410684100?lang=en_us&edition=fundamental","pubTime":"2024-02-12 21:00","pubTimestamp":1707742800,"startTime":"0","endTime":"0","summary":"-- Projected Cash Runway Extends into Second Calendar Quarter 2026, Well. Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application . -- Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track. -- Poster Highlighting the STRIVE-ON Trial Presented at 2024 International. The Company reported a net loss of $2.4 million, or $0.21 per share, for the three months ended December 31, 2023, a decrease of $1.5 million from the net loss of $3.9 million, or $0.52 per share, for the three months ended December 31, 2022. The Company's net loss of $2.4 million for the three months ended","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","BK4588","LU2357305700.SGD","BK4512","LU1548497426.USD","BK4007","LU0348723411.USD","LU1720051017.SGD","ACST","BK4141","ON","LU1861220033.SGD","LU1854103824.USD","LU1720051108.HKD","BK4585","LU1854104046.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acasti.com","stockEarnings":[{"period":"1week","weight":-0.0875},{"period":"1month","weight":0.0699},{"period":"3month","weight":-0.1487},{"period":"6month","weight":0.0735},{"period":"1year","weight":-0.0732},{"period":"ytd","weight":0.0104}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":0.0341},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1633},{"period":"1year","weight":0.2302},{"period":"ytd","weight":0.1473}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.049456},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.029985},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.04073},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.051963},{"month":5,"riseRate":0.583333,"avgChangeRate":-0.006603},{"month":6,"riseRate":0.5,"avgChangeRate":0.006072},{"month":7,"riseRate":0.5,"avgChangeRate":0.169201},{"month":8,"riseRate":0,"avgChangeRate":-0.187387},{"month":9,"riseRate":0.454545,"avgChangeRate":0.084826},{"month":10,"riseRate":0,"avgChangeRate":-0.151802},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.034336},{"month":12,"riseRate":0.727273,"avgChangeRate":0.06653}],"exchange":"NASDAQ","name":"Acasti Pharma","nameEN":"Acasti Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acasti Pharma(ACST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acasti Pharma,ACST,Acasti Pharma股票,Acasti Pharma股票老虎,Acasti Pharma股票老虎国际,Acasti Pharma行情,Acasti Pharma股票行情,Acasti Pharma股价,Acasti Pharma股市,Acasti Pharma股票价格,Acasti Pharma股票交易,Acasti Pharma股票购买,Acasti Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acasti Pharma(ACST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acasti Pharma(ACST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction